Shanghai Meiyue Biotech Development Co. Ltd.

Primary objective: To evaluate the efficacy of MY008211A tablets in the treatment of subjects with paroxysmal nocturnal hemoglobinuria on Day (D) 84, using the proportion of subjects whose hemoglobin (Hb) concentration increased by ≥20 g/L compared with baseline in subjects who did not receive red blood cell transfusion after 4 weeks of dosing. Secondary objective: To evaluate the safety and efficacy of MY008211A tablets in subjects with paroxysmal nocturnal hemoglobinuria. Exploratory objective: To explore the pharmacokinetic (PK) and pharmacodynamic (PD) characteristics of MY008211A tablets in subjects with paroxysmal nocturnal hemoglobinuria.

Primary study objective: To evaluate the safety and tolerability of MY008211A tablets 1200mg and 1600mg after a single oral administration in healthy Chinese volunteers; Secondary study objective: To evaluate the pharmacokinetic characteristics of MY008211A tablets 1200mg and 1600mg after a single oral administration in healthy Chinese volunteers; Exploratory objective: To explore the types of metabolites of MY008211A tablets in human plasma, the levels of pharmacodynamic-related markers, and their relationship with the PK parameters of MY008211A tablets.

Primary objective: To evaluate the effect of MY004567 tablets on the pharmacokinetic (PK) characteristics of oral methotrexate tablets in healthy adult subjects. Secondary objective: To evaluate the safety of MY004567 tablets and methotrexate tablets after oral administration in healthy adult subjects.